|
US5234991A
(en)
|
1975-07-29 |
1993-08-10 |
Pasteur Merieux Serums And Vaccines |
Porous mineral support coated with an aminated polysaccharide polymer
|
|
US4652639A
(en)
|
1982-05-06 |
1987-03-24 |
Amgen |
Manufacture and expression of structural genes
|
|
US4511503A
(en)
|
1982-12-22 |
1985-04-16 |
Genentech, Inc. |
Purification and activity assurance of precipitated heterologous proteins
|
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
|
US4631211A
(en)
|
1985-03-25 |
1986-12-23 |
Scripps Clinic & Research Foundation |
Means for sequential solid phase organic synthesis and methods using the same
|
|
US5250421A
(en)
|
1986-01-03 |
1993-10-05 |
Genetics Institute, Inc. |
Method for producing factor VIII:C-type proteins
|
|
US5149637A
(en)
|
1987-04-06 |
1992-09-22 |
Scripps Clinic & Research Foundation |
Recombinant Factor VIIIC fragments
|
|
US5043429B1
(en)
|
1987-05-01 |
1997-10-14 |
Scripps Research Inst |
Protein fragments containing factor VIII binding domain of von willebrand factor
|
|
FR2616437B1
(fr)
|
1987-06-11 |
1990-09-07 |
Ibf |
Polymeres composites, leur preparation et leur utilisation en chromatographie liquide
|
|
US5200510A
(en)
*
|
1987-06-16 |
1993-04-06 |
Zymogenetics, Inc. |
Method for purifying factor viii:c, von willebrand factor and complexes thereof
|
|
US4965195A
(en)
|
1987-10-26 |
1990-10-23 |
Immunex Corp. |
Interleukin-7
|
|
US4968607A
(en)
|
1987-11-25 |
1990-11-06 |
Immunex Corporation |
Interleukin-1 receptors
|
|
US5683912A
(en)
|
1994-07-21 |
1997-11-04 |
The Salk Institute For Biological Studies |
Cloning and expression of a novel acetylcholine-gated ion channel receptor subunit
|
|
FR2632309B1
(fr)
|
1988-06-07 |
1990-08-24 |
Lille Transfusion Sanguine |
Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
|
|
AU643427B2
(en)
|
1988-10-31 |
1993-11-18 |
Immunex Corporation |
Interleukin-4 receptors
|
|
US5073627A
(en)
|
1989-08-22 |
1991-12-17 |
Immunex Corporation |
Fusion proteins comprising GM-CSF and IL-3
|
|
FR2657884B1
(fr)
|
1990-02-05 |
1994-09-02 |
Tm Innovation |
Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
|
|
US5350683A
(en)
|
1990-06-05 |
1994-09-27 |
Immunex Corporation |
DNA encoding type II interleukin-1 receptors
|
|
WO1991018982A1
(en)
|
1990-06-05 |
1991-12-12 |
Immunex Corporation |
Type ii interleukin-1 receptors
|
|
US5661008A
(en)
|
1991-03-15 |
1997-08-26 |
Kabi Pharmacia Ab |
Recombinant human factor VIII derivatives
|
|
EP0590048B1
(en)
*
|
1991-06-20 |
2004-12-01 |
Aventis Behring L.L.C. |
A process for preparing therapeutic fragments of von willebrand factor
|
|
DE4204694C3
(de)
*
|
1992-02-01 |
1995-10-12 |
Octapharma Ag |
Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie
|
|
US5364771A
(en)
|
1992-04-07 |
1994-11-15 |
Emory University |
Hybrid human/porcine factor VIII
|
|
US5268097A
(en)
|
1992-06-19 |
1993-12-07 |
Sepracor Inc. |
Passivated and stabilized porous mineral oxide supports and method for the preparation and use of same
|
|
WO1994011384A1
(en)
|
1992-11-13 |
1994-05-26 |
Immunex Corporation |
Novel cytokine designated elk ligand
|
|
DE4435485C1
(de)
|
1994-10-04 |
1996-03-21 |
Immuno Ag |
Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
|
|
US5849989A
(en)
|
1994-10-07 |
1998-12-15 |
Ontogeny, Inc. |
Insulin promoter factor, and uses related thereto
|
|
US5688912A
(en)
|
1995-09-22 |
1997-11-18 |
Bayer Corporation |
Peptide ligands which bind to von willebrand factor
|
|
DE69701671T3
(de)
|
1996-01-23 |
2006-08-17 |
Qiagen Genomics, Inc., Bothell |
Verfahren und zusammenstellungen zur sequenzbestimmung von nukleinsäuremolekülen
|
|
US6613508B1
(en)
|
1996-01-23 |
2003-09-02 |
Qiagen Genomics, Inc. |
Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
|
|
US6312893B1
(en)
|
1996-01-23 |
2001-11-06 |
Qiagen Genomics, Inc. |
Methods and compositions for determining the sequence of nucleic acid molecules
|
|
AT403765B
(de)
|
1996-04-12 |
1998-05-25 |
Immuno Ag |
Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex
|
|
AU3671197A
(en)
|
1996-07-19 |
1998-02-10 |
Regents Of The University Of Michigan, The |
Dna encoding canine von willebrand factor and methods of use
|
|
US6074832A
(en)
|
1996-07-19 |
2000-06-13 |
The Regents Of The University Of Michigan |
DNA encoding canine von Willebrand factor and methods of use
|
|
US6063593A
(en)
|
1996-11-12 |
2000-05-16 |
University Of Southern California University Park Campus |
TGFβ1 responsive bone marrow derived cells to express a recombinant protein
|
|
DE69738075T2
(de)
|
1996-11-27 |
2008-05-21 |
Genentech, Inc., South San Francisco |
Affinitätsreinigung von polypeptiden an einer protein a-matrix
|
|
AT406373B
(de)
|
1997-02-27 |
2000-04-25 |
Immuno Ag |
Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
|
|
AT406867B
(de)
|
1997-02-27 |
2000-10-25 |
Immuno Ag |
Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
|
|
AU6782198A
(en)
|
1997-03-27 |
1998-10-20 |
Trustees Of Boston University |
Novel antiplatelet agent
|
|
US5804420A
(en)
|
1997-04-18 |
1998-09-08 |
Bayer Corporation |
Preparation of recombinant Factor VIII in a protein free medium
|
|
EP1000176A1
(en)
|
1997-07-22 |
2000-05-17 |
Rapigene, Inc. |
Computer method and system for correlating sequencing data by ms
|
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
EP1129186B2
(de)
|
1998-11-10 |
2016-11-30 |
Stichting Sanquin Bloedvoorziening |
Ein faktor viii-polypeptid mit faktor viii:c-aktivität
|
|
US7144996B1
(en)
|
1999-03-05 |
2006-12-05 |
Genentech, Inc. |
Nucleic acid encoding human suppressor of fused
|
|
US20060099685A1
(en)
|
1999-04-15 |
2006-05-11 |
Yallop Christopher A |
Recombinant expression of factor VIII in human cells
|
|
US6855544B1
(en)
|
1999-04-15 |
2005-02-15 |
Crucell Holland B.V. |
Recombinant protein production in a human cell
|
|
US7604960B2
(en)
|
1999-04-15 |
2009-10-20 |
Crucell Holland B.V. |
Transient protein expression methods
|
|
US20050164386A1
(en)
|
1999-04-15 |
2005-07-28 |
Uytdehaag Alphonsus G. |
Overexpression of enzymes involved in post-translational protein modifications in human cells
|
|
EP1240337B1
(en)
|
1999-12-24 |
2006-08-23 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
|
AU2001275091A1
(en)
|
2000-06-02 |
2001-12-17 |
Blue Heron Biotechnology, Inc. |
Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
|
|
US7498304B2
(en)
|
2000-06-16 |
2009-03-03 |
Curis, Inc. |
Angiogenesis-modulating compositions and uses
|
|
AU2001277217A1
(en)
|
2000-07-28 |
2002-02-13 |
Blood Center Research Foundation |
Synthetic and recombinant substrates for the detection of the von willebrand factor-cleaving protease
|
|
AUPR278301A0
(en)
|
2001-01-31 |
2001-02-22 |
Bionomics Limited |
A novel gene
|
|
JP2003284570A
(ja)
*
|
2001-04-25 |
2003-10-07 |
Chemo Sero Therapeut Res Inst |
フォンビルブラント因子（ｖＷＦ）切断酵素
|
|
WO2003025146A2
(en)
|
2001-09-18 |
2003-03-27 |
Avigenics, Inc. |
Production of a transgenic avian by cytoplasmic injection
|
|
US7439043B2
(en)
|
2001-10-10 |
2008-10-21 |
Neose Technologies, Inc. |
Galactosyl nucleotide sugars
|
|
US20040249134A1
(en)
|
2001-11-30 |
2004-12-09 |
Lollar John S. |
Factor viii c2 domain variants
|
|
AU2002357249A1
(en)
|
2001-12-13 |
2003-07-09 |
Blue Heron Biotechnology, Inc. |
Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
|
|
WO2003059934A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7317091B2
(en)
*
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
EP1543106B1
(en)
|
2002-07-15 |
2007-04-11 |
Immunex Corporation |
Methods and media for controlling sialylation of proteins produced by mammalian cells
|
|
US7348004B2
(en)
*
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
PL2298347T3
(pl)
*
|
2003-05-06 |
2016-03-31 |
Bioverativ Therapeutics Inc |
Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
|
|
JP2005073528A
(ja)
*
|
2003-08-28 |
2005-03-24 |
Genetics Inst Llc |
生物学的系における生物学的組織への血球の接着を阻害する方法、ならびにその方法に使用するための組成物
|
|
WO2005037867A1
(en)
|
2003-10-15 |
2005-04-28 |
Pdl Biopharma, Inc. |
ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
|
|
US7211559B2
(en)
|
2003-10-31 |
2007-05-01 |
University Of Maryland, Baltimore |
Factor VIII compositions and methods
|
|
EP3184551A1
(en)
|
2004-08-12 |
2017-06-28 |
Lipoxen Technologies Limited |
Sialic acid derivatives
|
|
KR20070101226A
(ko)
|
2004-09-07 |
2007-10-16 |
아케믹스 코포레이션 |
앱타머의 약화학
|
|
GB0423974D0
(en)
|
2004-10-28 |
2004-12-01 |
Ares Trading Sa |
Proteins
|
|
CN101163506B
(zh)
|
2004-12-27 |
2012-09-26 |
巴克斯特国际公司 |
聚合物-von Willebrand因子偶联物
|
|
WO2006074947A2
(en)
|
2005-01-14 |
2006-07-20 |
Ablynx N.V. |
METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
|
|
EP1739179A1
(en)
|
2005-06-30 |
2007-01-03 |
Octapharma AG |
Serum-free stable transfection and production of recombinant human proteins in human cell lines
|
|
US20080206246A1
(en)
|
2006-04-05 |
2008-08-28 |
Ravetch Jeffrey V |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
|
WO2007102946A2
(en)
*
|
2006-01-23 |
2007-09-13 |
Amgen Inc. |
Crystalline polypeptides
|
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
|
JP2009539412A
(ja)
|
2006-06-12 |
2009-11-19 |
レセプター バイオロジックス， インコーポレイテッド |
汎細胞表面レセプター特異的な治療薬
|
|
PT2101821E
(pt)
|
2006-12-15 |
2014-10-03 |
Baxter Int |
Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
|
|
CA2673459C
(en)
*
|
2006-12-22 |
2016-09-13 |
Stefan Schulte |
Modified coagulation factors with prolonged in vivo half-life
|
|
NZ585530A
(en)
|
2007-12-27 |
2012-06-29 |
Baxter Int |
Methods for differentiating plasma-derived protein from recombinant protein in a sample
|
|
SG187410A1
(en)
|
2007-12-28 |
2013-02-28 |
Baxter Int |
Recombinant vwf formulations
|
|
PL2291523T3
(pl)
*
|
2008-06-24 |
2015-05-29 |
Csl Behring Gmbh |
Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo
|
|
MX2011001624A
(es)
|
2008-08-21 |
2011-03-28 |
Octapharma Ag |
Factor viii y ix humano producido en forma recombinante.
|
|
US20110086362A1
(en)
|
2009-10-09 |
2011-04-14 |
Massachusetts Institute Of Technology |
High-Throughput Method for Quantifying Sialylation of Glycoproteins
|
|
WO2011060242A2
(en)
|
2009-11-13 |
2011-05-19 |
Talecris Biotherapeutics, Inc. |
Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
|